Definium Therapeutics Appoints Roger Adsett to Board of Directors

Article content

Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium’s next phase of growth

Article content

NEW YORK — Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately.

Article content

Article content

“We are thrilled to welcome Roger to our Board of Directors,” said Rob Barrow, Chief Executive Officer of Definium Therapeutics. “Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he’s led the development of world-class commercial and operational capabilities supporting the company on its mission to transform the lives of patients facing serious diseases. His ability to translate innovative science into disciplined, large-scale commercial execution will be especially valuable as we approach three anticipated Phase 3 readouts in 2026 and prepare to bring transformative therapies to patients.”

Article content

Article content

Mr. Adsett is a highly accomplished biopharmaceutical executive with more than two decades of experience leading landmark drug launches, scaling global commercial organizations, and helping companies establish leadership positions within their therapeutic areas, including specialty, rare disease, and primary care markets.

Article content

Article content

“I’ve admired Definium’s commitment to scientific rigor and its ambition to redefine the treatment landscape for people living with mental health disorders,” said Mr. Adsett. “It’s an honor to join the Board at this pivotal moment and to collaborate with leaders committed to advancing compelling clinical research into therapies that drive meaningful value for patients and shareholders.”

Article content

About Roger Adsett

Article content

Mr. Adsett currently serves as Chief Operating Officer of Insmed, a position he has held since November 2019 after serving as Chief Commercial Officer from 2016 to 2019. In these roles, he has overseen commercial strategy and execution, operational excellence, and enterprise-wide growth initiatives. He played a central role in building Insmed’s global commercial organization and supporting the launch and growth of ARIKAYCE^® and BRINSUPRI^® establishing Insmed as a fully integrated commercial biopharmaceutical company. Prior to Insmed, Mr. Adsett held a series of senior leadership positions at Shire from 2005 to 2016, where he was responsible for global commercial operations across six specialty and two rare-disease brands. Earlier in his career, Mr. Adsett spent 11 years at AstraZeneca, where he held a variety of commercial leadership roles, including as marketing director for the U.S. launch of Nexium^®, a blockbuster therapy for gastroesophageal reflux disease, and as global brand director for Symbicort^®, a leading treatment for asthma and chronic obstructive pulmonary disease. Prior to AstraZeneca, he spent three years at Accenture. He also served on the Board of Directors of Landos Biopharma, Inc. from March 2022 until its acquisition by AbbVie in May 2024, where he contributed to the company’s governance and strategic direction as a member of the Audit Committee.

Article content

Mr. Adsett holds a master of business administration from the Wharton School at the University of Pennsylvania and a bachelor’s degree in English and economics from Bucknell University.

Article content

About Definium Therapeutics

Article content

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

Article content

Article content

Article content

Article content

Article content

View source version on businesswire.com:

Article content

Article content

Article content

Contacts

Article content

For further information, please contact:

Article content

Investors:
Gitanjali Jain
VP, Head of Investor Relations
[email protected]

Article content

Article content